News · 26 weeks410%
2026-04-192026-10-11
Mix2690d
- Insider11(42%)
- Other8(31%)
- SEC Filings6(23%)
- Earnings1(4%)
Latest news
25 items- PRFemasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth ControlATLANTA, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that it has doubled the number of actively enrolling sites in its FemBloc® FINALE Pivotal Trial to twelve across the United States. The coast-to-coast network of academic centers and private clinical practices now includes Baylor Research Institute and Columbia University Medical Center, joining existing academic sites Maimonides Medical Center, Stanford University, University of California Davi
- PRFemasys to Exhibit at the ASRM 2026 Scientific Congress & ExpoATLANTA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that it will exhibit at the American Society for Reproductive Medicine (ASRM) 2026 Scientific Congress & Expo, taking place October 24–28 at the Baltimore Convention Center in Baltimore, Maryland. The Company will highlight FemaSeed® Intratubal Insemination (ITI), a first-step fertility treatment option, together with FemVue®, its complementary diagnostic solution for in-office fallopian tube ev
- SECSEC Form 424B3 filed by Femasys Inc.424B3 - FEMASYS INC (0001339005) (Filer)
- SECSEC Form EFFECT filed by Femasys Inc.EFFECT - FEMASYS INC (0001339005) (Filer)
- PRFemasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care-- Leading multi-site OB/GYN health practice to implement FemVue® for fertility diagnostic evaluation and FemaSeed for first-line treatment across all four locations -- ATLANTA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that Minnesota Women’s Care will implement FemVue for fertility diagnostic evaluation and FemaSeed Complete for in-office first-line fertility treatment across its four OB/GYN practice locations. "We are excited to see Minneso
- PRFemasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility PortfolioATLANTA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today a partnership with CapexMD to expand patient access to its FemaSeed-led fertility portfolio through dedicated financing solutions. The partnership will support access to FemaSeed Complete, an in-office intratubal insemination solution designed as a first-line fertility treatment, together with Femasys’ female and male fertility diagnostics, FemVue® and SpermVue®, across OB/GYN practices and fer
- SECSEC Form S-3 filed by Femasys Inc.S-3 - FEMASYS INC (0001339005) (Filer)
- PRFemasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations-- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue® fertility evaluation and FemaSeed as a first-line treatment option -- ATLANTA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today a partnership with UNC Health to introduce its female and male fertility diagnostics, FemVue and SpermVue™, together with FemaSeed Complete, an in-office intratubal insemination solution designed as a first-line fertility treatment
- SECSEC Form D filed by Femasys Inc.D - FEMASYS INC (0001339005) (Filer)
- PRFemasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®ATLANTA, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that the U.S. Food and Drug Administration has approved the Company’s modular premarket approval application (PMA) pathway for FemBloc, its investigational non-surgical permanent birth control technology in the United States. FemBloc is approved for marketing in Europe and other select international markets. "FDA approval of the modular PMA pathway provides a clear and efficient framework for a
- SECSEC Form 10-Q filed by Femasys Inc.10-Q - FEMASYS INC (0001339005) (Filer)
- PRFemasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update-- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed® fertility portfolio and advancement of the FemBloc® clinical and regulatory program toward U.S. approval -- ATLANTA, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announces its financial results for the quarter ended June 30, 2026 and provides a corporate update. Corporate Highlights from 2Q 2026 to date Completed $30 million private placement with potential proceeds of up t
- PRFemasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents-- New U.S. and international patents complement existing delivery system patents, extending global IP coverage for the FemBloc solution -- ATLANTA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today the issuance of patents in the United States and key international markets that expand intellectual property protection for the blended polymer component of FemBloc, the Company’s non-surgical permanent birth control technology. These patents broaden and ex
- INSIDERSEC Form 4 filed by Director Eichenbaum Kenneth D.4 - FEMASYS INC (0001339005) (Issuer)
- INSIDERSEC Form 4 filed by Director Uzialko Edward R4 - FEMASYS INC (0001339005) (Issuer)
- INSIDERSEC Form 4 filed by Director Milnes Alistair4 - FEMASYS INC (0001339005) (Issuer)
- INSIDERSEC Form 4 filed by Director Larsen Charles4 - FEMASYS INC (0001339005) (Issuer)
- INSIDERChief Clinical-Medical Affairs Mifek Jeffrey Gerald bought $10,000 worth of shares (3,125 units at $3.20) (SEC Form 4)4 - FEMASYS INC (0001339005) (Issuer)
- INSIDERSEC Form 4 filed by Chief Clinical-Medical Affairs Mifek Jeffrey Gerald4 - FEMASYS INC (0001339005) (Issuer)
- INSIDERNew insider Mifek Jeffrey Gerald claimed ownership of 1,411 shares (SEC Form 3)3 - FEMASYS INC (0001339005) (Issuer)
- INSIDERChief Technology Officer Sipos Jeremy Alexander bought $10,000 worth of shares (3,125 units at $3.20) (SEC Form 4)4 - FEMASYS INC (0001339005) (Issuer)
- INSIDERChief Operating Officer Canning John Charles bought $14,000 worth of shares (4,375 units at $3.20) (SEC Form 4)4 - FEMASYS INC (0001339005) (Issuer)
- INSIDERChief Financial Officer Elefant Dov bought $50,000 worth of shares (15,625 units at $3.20) (SEC Form 4)4 - FEMASYS INC (0001339005) (Issuer)
- INSIDERChief Executive Officer Lee-Sepsick Kathy bought $50,000 worth of shares (15,625 units at $3.20) (SEC Form 4)4 - FEMASYS INC (0001339005) (Issuer)
- SECFemasys Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - FEMASYS INC (0001339005) (Filer)
FEMY FAQ
7 questionsWhat does Femasys Inc. do?
Femasys Inc., a biomedical company, researches, develops, and manufactures medical devices for the women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a sterile, single-use disposable endocervical curettage product; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its...Where does FEMY stock trade?
Femasys Inc. (FEMY) is listed on NASDAQ.What sector and industry is FEMY in?
Femasys Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Femasys Inc. go public?
Femasys Inc. (FEMY) completed its IPO in 2021.What are analysts saying about FEMY?
Femasys Inc. has had 3 recent analyst actions on file. The most recent action was from Laidlaw: Buy with a $650.00 price target on 2025-11-20. Recent price targets range from $650.00 to $2500.00.What companies are similar to FEMY?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare FEMY side-by-side with any of them on Quantisnow.How can I track FEMY on Quantisnow?
Quantisnow aggregates Femasys Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FEMY to receive live email and push alerts on every new disclosure.